Abbvie INC 8-K filings

AbbVie has revised its 2024 earnings guidance downward due to a significant $937 million expense related to acquired IPR&D and milestones in the second quarter.

AbbVie has announced the appointment of a new CEO, effective July 1, 2024, along with the results of their 2024 Annual Meeting of Stockholders.

AbbVie's first-quarter results show a mixed performance with increased revenue and GAAP EPS, but a decrease in adjusted EPS, alongside a leadership transition and raised full-year guidance.

AbbVie has revised its 2024 earnings guidance to incorporate a $164 million expense related to acquired IPR&D and milestones, impacting both GAAP and adjusted non-GAAP diluted earnings per share.

AbbVie has successfully priced a $15 billion offering of senior notes to finance its acquisition of Cerevel Therapeutics, repay a term loan related to the ImmunoGen acquisition, and for general corporate purposes.

AbbVie has appointed Robert A. Michael as its new CEO, succeeding Richard A. Gonzalez who will transition to Executive Chairman, effective July 1, 2024.

AbbVie has completed its acquisition of ImmunoGen, adding the antibody-drug conjugate ELAHERE to its portfolio and updating its 2024 EPS guidance to reflect the deal's dilutive impact.

AbbVie's full-year 2023 results show a decrease in GAAP EPS and revenue, impacted by Humira biosimilar competition, but the company is making strategic acquisitions and raising long-term outlook for key products.